Jeevanandham Somasundaram

Prof. Dr. Jeevanandham Somasundaram

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Asian Journal of Pharmaceutics
Verified
Journal Article
Closed access
Jeevanandham SomasundaramJeevanandham Somasundaram
Jeevanandham Somasundaram
DDD Dhachinamoorthi
D Dhachinamoorthi
KSKb Chandra Sekhar
Kb Chandra Sekhar
M. MuthukumaranM. Muthukumaran
M. Muthukumaran
NSN Sriram
N Sriram
JJJ Joysaruby
J Joysaruby

1 January 2010 in Asian Journal of Pharmaceutics
Verified
Journal Article
Closed access
PDF file
Jeevanandham SomasundaramJeevanandham Somasundaram
Jeevanandham Somasundaram
DDD Dhachinamoorthi
D Dhachinamoorthi
VSV Senthil
V Senthil
SCSekharK.B Chandra
SekharK.B Chandra
Oral mucoadhesive sustained drug delivery systems of salbutamol sulfate were formulated using an isolated natural agent from the seeds of Caesalpinia pulcherrima. The isolated material was evaluated for various parameters, such as, melting point, viscosity, pH, elemental analysis, swelling index, phytochemical constituents, and solubility studies. The mucoadhesive characters of the isolated substance were identified by a comparative study with hydroxyl propyl cellulose and sodium alginate, by various in vitro methods, such as, Shear stress measurement, Wilhelmy's method, Falling sphere method, and Detachment force measurement. Formulation and evaluation of mucoadhesive oral tablets of salbutamol sulfate (100 mg), using isolated natural materials in different proportions, and in vitro release studies, were carried out for three different formulations according to the U.S.P apparatus two (paddle method). Each 100 mg tablet was taken in 900 ml of acid buffer 1.2 and maintained at 37˚C. After two hours the filtrate was collected and replaced in buffer 7.4. In vitro releases of three different formulations for nine hours were studied, which showed the sustained action of drug release with increasing the concentration of the isolated natural mucoadhesive agent in the formulations.

10 April 2026 in International Journal of Drug Delivery Technology
Verified
Journal Article
Closed access
VBVirupaxappa Biradar
Virupaxappa Biradar
GKGiridhar Kunamaneni
Giridhar Kunamaneni
NVNina Varghese
Nina Varghese
BKB. Hema Kiranmayi
B. Hema Kiranmayi
BMBoboxonova Muhayyoxon Mo'Minjonovna
Boboxonova Muhayyoxon Mo'Minjonovna
Jeevanandham SomasundaramJeevanandham Somasundaram
Jeevanandham Somasundaram
Alzheimer's disease (AD) represents the most prevalent and devastating form of age-related neurodegenerative disorder, characterized by progressive cognitive decline, memory impairment, and neuropsychiatric symptoms that arise from the accumulation of amyloid-beta (Aβ) plaques, neurofibrillary tau tangles, and chronic neuroinflammation. A major obstacle in the pharmacological management of AD is the inability of most therapeutic agents to cross the blood-brain barrier (BBB) in therapeutically meaningful concentrations following conventional systemic administration. The present investigation focuses on the design, fabrication, and comprehensive in vitro characterization of functionalized polymeric nanoparticles (NPs) loaded with Donepezil hydrochloride (DPZ), a first-line acetylcholinesterase inhibitor, intended for intranasal delivery as a novel cognitive restoration platform in Alzheimer's disease. Poly(lactic-co-glycolic acid) (PLGA) and chitosan were selected as the primary polymeric matrices and surface-functionalization agents, respectively, owing to their well-established biocompatibility, biodegradability, mucoadhesive properties, and ability to enhance cellular uptake. Eight distinct nanoparticle formulations (F1–F8) were systematically developed by varying PLGA concentration, chitosan coating levels, drug-to-polymer ratios, and the addition of stabilizers such as polyvinyl alcohol (PVA). The formulations were evaluated for particle size, polydispersity index (PDI), zeta potential, encapsulation efficiency (EE%), drug loading (DL%), in vitro drug release behavior using Franz diffusion cells, mucoadhesive strength, and ex vivo nasal permeation. Optimized formulations demonstrated particle sizes in the range of 145–310 nm, positive zeta potentials (due to chitosan coating), encapsulation efficiencies exceeding 72%, and sustained biphasic drug release profiles extending over 24 hours, with enhanced mucoadhesive properties suitable for prolonged olfactory epithelium contact time. The results demonstrate that chitosan-coated PLGA nanoparticles represent an effective and tunable platform for nose-to-brain delivery of anti-Alzheimer drugs, with significant potential for advancing translational research in neurodegenerative disease therapy. Keywords: Alzheimer's disease; nose-to-brain delivery; PLGA nanoparticles; chitosan; intranasal drug delivery; bloodbrain barrier; donepezil.

2 June 2024
Verified
Book Chapter
Closed access
PDF file
KRKonatham Teja Kumar Reddy
Konatham Teja Kumar Reddy
NVN. Venkatesan
N. Venkatesan
MSM. V. Saranya
M. V. Saranya
Jeevanandham SomasundaramJeevanandham Somasundaram
Jeevanandham Somasundaram
JGJeetendra Kumar Gupta
Jeetendra Kumar Gupta
ASAnasuya Patil Surfactant-Tween
Anasuya Patil Surfactant-Tween

1 September 2011
Verified
Closed access
PDF file
Jeevanandham SomasundaramJeevanandham Somasundaram
Jeevanandham Somasundaram
DDDuraiswamy Dhachinamoorthi
Duraiswamy Dhachinamoorthi
KSKothapalli Bannoth Chandra Sekhar
Kothapalli Bannoth Chandra Sekhar